Heat Biologics Inc. (HTBX) 0.80 $HTBX
Heat Biologics Presents a Poster on its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial at ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 6:00AM CDT
-- Poster reviews trial design and endpoints
HTBX: 0.80 (+0.17)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 0.80 (+0.17), SNTA: 0.31 (unch), CTIC: 0.40 (+0.01), LPTN: 2.36 (-0.09)
Heat Biologics to Present at PIONEERS 2016, Presented by Joseph Gunnar & Co.
GlobeNewswire - Tue Apr 26, 6:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is scheduled to present at PIONEERS 2016, presented by Joseph Gunnar & Co., on Thursday, May 5, 2016 at 4:00 p.m. Eastern Time.
HTBX: 0.80 (+0.17)
Heat Biologics Appoints Dr. John Prendergast to Board of Directors
GlobeNewswire - Mon Apr 25, 6:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company has appointed John Prendergast, Ph.D., to its Board of Directors, effective April 21, 2016. Dr. Prendergast will replace Paul Belsky, M.D., who has served on Heat's board since 2009.
HTBX: 0.80 (+0.17)
Heat Biologics and OncoSec Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Mon Apr 18, 5:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that preclinical data from its collaboration with OncoSec Medical Incorporated ("OncoSec" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org).
HTBX: 0.80 (+0.17)
OncoSec and Heat Biologics Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
PR Newswire - Mon Apr 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced that preclinical data from its collaboration with Heat Biologics, Inc. ("Heat" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org).
HTBX: 0.80 (+0.17), ONCS: 1.60 (-0.04)
Targeting an $11 Billion Market, Heat Biologics' Cancer Vaccines Provide Investors a Huge Opportunity
ACCESSWIRE - Fri Apr 15, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Cancer news seen on all types of media - television, radio, print, webinars, investor and scientific meetings, and grass root blogs, is covered for a reason. Up to 40% of people in the US alone develop cancer, according the National Cancer Institute. Breast cancer and leukemia get the lion's share of attention, but other cancers are just as dangerous. I believe Heat Biologics (NasdaqCM: HTBX), one of the most forward-thinking and innovative companies in cancer immunotherapy geared toward cures for non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC), will be a winner in the race to bring medicine a giant step forward.
HTBX: 0.80 (+0.17), MRK: 57.68 (+0.64), SNY: 41.19 (+0.90)
Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 12, 5:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced three poster presentations at the AACR Annual Meeting, including initial preclinical results from Heat's collaboration with OncoSec Medical Incorporated, a biotechnology company developing DNA-based intra-tumoral cancer immunotherapies. The AACR Annual Meeting is being held on April 16-20, 2016 in New Orleans, LA.
HTBX: 0.80 (+0.17)
Heat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestones
GlobeNewswire - Thu Apr 07, 6:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is implementing cost-saving measures and a focused corporate strategy to achieve, with its current cash on-hand, data readout in the fourth quarter of 2016 for its lead Phase 2 program evaluating HS-410 for the treatment of non-muscle invasive bladder cancer. These cost-saving measures include a workforce reduction of approximately 22% of the company's headcount and a reduction in compensation for the remaining leadership team. Heat also announced the voluntary resignation of two members from its Board of Directors. In addition, Heat will further decrease operating expenses by advancing only the eight patients currently enrolled in its Phase 1b clinical trial evaluating HS-110 for the treatment of non-small cell lung cancer instead of enrolling the eighteen patients initially planned. Heat intends to focus its resources to achieve the important near-term milestones for these two product candidates, both of which are expecting topline data in the fourth quarter of 2016.
HTBX: 0.80 (+0.17)
Heat Biologics to Participate in the 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
GlobeNewswire - Wed Mar 30, 6:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat's Chief Scientific Officer, will participate in the 6 Annual Cancer Immunotherapy: A Long-Awaited Reality Conference being held Thursday, March 31, 2016 at the Apella Event Space at Alexandria Center in New York City. Dr. Schreiber will join a panel discussion starting at 11:00 a.m. ET entitled "Therapeutic Cancer Vaccines: Stimulating the Immune System," as well as a second panel discussion starting at 4:30 p.m. ET entitled "Combination Immuno-Oncology Themes."
HTBX: 0.80 (+0.17)
Heat Biologics Announces Closing of Public Offering
GlobeNewswire - Wed Mar 23, 10:05AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced the closing of its previously announced underwritten public offering of 9,100,000 shares of its common stock and warrants to purchase up to an aggregate of 6,825,000 shares of its common stock at a combined public offering price of $0.75 per share and related warrant. Each share of its common stock was sold together with a warrant to purchase 0.75 of a share of its common stock. The gross proceeds from this offering were approximately $6.8 million, before deducting the underwriting discount and estimated offering expenses payable by Heat, but excluding proceeds from the exercise of any warrants.
HTBX: 0.80 (+0.17)
These Penny Stocks to Watch Should Be On Your List Friday 3/18/2016, If You Choose
ACCESSWIRE - Fri Mar 18, 11:12AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 18, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. CLF, ECR, TBIO, and HTBX have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, NASDAQ, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
HTBX: 0.80 (+0.17), ECR: 4.32 (+0.17), TBIO: 0.58 (-0.01), CLF: 5.25 (+0.16)
Heat Biologics Announces Public Offering of Common Stock and Warrants
GlobeNewswire - Fri Mar 18, 7:30AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that it has priced an underwritten public offering of 9,100,000 shares of its common stock and warrants to purchase up to an aggregate of 6,825,000 shares of its common stock at a combined public offering price of $0.75 per share and related warrant. Each share of its common stock is being sold together with a warrant to purchase 0.75 of a share of its common stock. The gross proceeds from this offering to Heat are expected to be approximately $6.8 million, before deducting the underwriting discount and estimated offering expenses payable by Heat, but excluding the exercise of any warrants.
HTBX: 0.80 (+0.17)
Penny Stocks to Buy on St. Patrick's Day... If You So Choose
ACCESSWIRE - Thu Mar 17, 10:54AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 17, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. HTBX, CLF, BTU, and ELTP have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
HTBX: 0.80 (+0.17), BTU: 2.07 (unch), CLF: 5.25 (+0.16)
Heat Biologics' CSO to Participate in the 27th Annual Cancer Progress Conference by Defined Health
GlobeNewswire - Wed Mar 09, 6:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat's Chief Scientific Officer, will participate in the 27 Annual Cancer Progress Conference by Defined Health being held in New York City. Dr. Schreiber will serve as a speaker on a panel entitled "Immuno-Oncology I: Attacking Cancer Antigens - Exploiting off-the-Shelf and Personalized Vaccines and Triggering of Immunogenic Cell Death," which takes place today at 9:15 a.m. Eastern Time.
HTBX: 0.80 (+0.17)
Heat Biologics Presents Positive ComPACT Preclinical Data at the Keystone Symposia
GlobeNewswire - Mon Mar 07, 3:05PM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that positive preclinical data from its next generation ComPACT platform technology, which combines a T cell priming vaccine and T cell co-stimulator in a single product, were presented as both an oral presentation and poster at the Keystone Symposia on Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, held in Whistler, British Columbia, Canada on March 6-10, 2016. Data presented showed that ComPACT secreting OX40L generated the most potent immune response among other ComPACT co-stimulator variations including TL1A, 4-1BBL and ICOSL, as well as compared to systemic delivery of OX40 agonist antibody and vaccine alone.
HTBX: 0.80 (+0.17)
Heat Biologics to Present at the 28th Annual ROTH Conference
GlobeNewswire - Fri Mar 04, 6:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is scheduled to present at the 28 Annual ROTH Conference on Tuesday, March 15, 2016 at 7:30 a.m. Pacific Time.
HTBX: 0.80 (+0.17)
FDA Lifts Heat Biologics Partial Clinical Hold
GlobeNewswire - Wed Feb 10, 6:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the company's Phase 2 clinical trial evaluating HS-410 either alone or in combination with standard of care Bacillus Calmette-Guerin (BCG), for the treatment of non-muscle invasive bladder cancer (NMIBC). Heat will resume patient enrollment.
HTBX: 0.80 (+0.17)
HIV-1 Infection - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8h7d/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Beth Israel Deaconess Medical Center, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Chipscreen Biosciences Ltd - CompleGen, Inc. - Critical Outcome Technologies Inc. - Cytodyn Inc. - Dong-A ST Co., Ltd. - Enzo Biochem, Inc. - Evofem, Inc. - FIT Biotech Oy - Formune S.L. - Frontier Biotechnologies Co., Ltd - GeneCure LLC - Genetic Immunity, Inc - Gilead Sciences, Inc. - GlaxoSmithKline Plc - H-Phar S.A. - Heat Biologics, Inc. - (20 Others) For more information visit http://www.researchandmarkets.com/research/px..._infection
HTBX: 0.80 (+0.17), ARGS: 5.60 (+0.14), ENZ: 5.92 (+0.15), GILD: 83.37 (+0.92), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)
Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference
GlobeNewswire - Tue Jan 26, 6:02AM CST
-- Early results support mechanism of action
HTBX: 0.80 (+0.17)
Heat Biologics Presents a Poster on its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial at ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 6:00AM CDT
-- Poster reviews trial design and endpoints
HTBX: 0.80 (+0.17)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 0.80 (+0.17), SNTA: 0.31 (unch), CTIC: 0.40 (+0.01), LPTN: 2.36 (-0.09)
Heat Biologics to Present at PIONEERS 2016, Presented by Joseph Gunnar & Co.
GlobeNewswire - Tue Apr 26, 6:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is scheduled to present at PIONEERS 2016, presented by Joseph Gunnar & Co., on Thursday, May 5, 2016 at 4:00 p.m. Eastern Time. HTBX: 0.80 (+0.17)
Heat Biologics Appoints Dr. John Prendergast to Board of Directors
GlobeNewswire - Mon Apr 25, 6:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company has appointed John Prendergast, Ph.D., to its Board of Directors, effective April 21, 2016. Dr. Prendergast will replace Paul Belsky, M.D., who has served on Heat's board since 2009. HTBX: 0.80 (+0.17)
Heat Biologics and OncoSec Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Mon Apr 18, 5:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that preclinical data from its collaboration with OncoSec Medical Incorporated ("OncoSec" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org). HTBX: 0.80 (+0.17)
OncoSec and Heat Biologics Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
PR Newswire - Mon Apr 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced that preclinical data from its collaboration with Heat Biologics, Inc. ("Heat" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org). HTBX: 0.80 (+0.17), ONCS: 1.60 (-0.04)
Targeting an $11 Billion Market, Heat Biologics' Cancer Vaccines Provide Investors a Huge Opportunity
ACCESSWIRE - Fri Apr 15, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Cancer news seen on all types of media - television, radio, print, webinars, investor and scientific meetings, and grass root blogs, is covered for a reason. Up to 40% of people in the US alone develop cancer, according the National Cancer Institute. Breast cancer and leukemia get the lion's share of attention, but other cancers are just as dangerous. I believe Heat Biologics (NasdaqCM: HTBX), one of the most forward-thinking and innovative companies in cancer immunotherapy geared toward cures for non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC), will be a winner in the race to bring medicine a giant step forward.
HTBX: 0.80 (+0.17), MRK: 57.68 (+0.64), SNY: 41.19 (+0.90)
Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 12, 5:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced three poster presentations at the AACR Annual Meeting, including initial preclinical results from Heat's collaboration with OncoSec Medical Incorporated, a biotechnology company developing DNA-based intra-tumoral cancer immunotherapies. The AACR Annual Meeting is being held on April 16-20, 2016 in New Orleans, LA. HTBX: 0.80 (+0.17)
Heat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestones
GlobeNewswire - Thu Apr 07, 6:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is implementing cost-saving measures and a focused corporate strategy to achieve, with its current cash on-hand, data readout in the fourth quarter of 2016 for its lead Phase 2 program evaluating HS-410 for the treatment of non-muscle invasive bladder cancer. These cost-saving measures include a workforce reduction of approximately 22% of the company's headcount and a reduction in compensation for the remaining leadership team. Heat also announced the voluntary resignation of two members from its Board of Directors. In addition, Heat will further decrease operating expenses by advancing only the eight patients currently enrolled in its Phase 1b clinical trial evaluating HS-110 for the treatment of non-small cell lung cancer instead of enrolling the eighteen patients initially planned. Heat intends to focus its resources to achieve the important near-term milestones for these two product candidates, both of which are expecting topline data in the fourth quarter of 2016. HTBX: 0.80 (+0.17)
Heat Biologics to Participate in the 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
GlobeNewswire - Wed Mar 30, 6:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat's Chief Scientific Officer, will participate in the 6 Annual Cancer Immunotherapy: A Long-Awaited Reality Conference being held Thursday, March 31, 2016 at the Apella Event Space at Alexandria Center in New York City. Dr. Schreiber will join a panel discussion starting at 11:00 a.m. ET entitled "Therapeutic Cancer Vaccines: Stimulating the Immune System," as well as a second panel discussion starting at 4:30 p.m. ET entitled "Combination Immuno-Oncology Themes." HTBX: 0.80 (+0.17)
Heat Biologics Announces Closing of Public Offering
GlobeNewswire - Wed Mar 23, 10:05AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced the closing of its previously announced underwritten public offering of 9,100,000 shares of its common stock and warrants to purchase up to an aggregate of 6,825,000 shares of its common stock at a combined public offering price of $0.75 per share and related warrant. Each share of its common stock was sold together with a warrant to purchase 0.75 of a share of its common stock. The gross proceeds from this offering were approximately $6.8 million, before deducting the underwriting discount and estimated offering expenses payable by Heat, but excluding proceeds from the exercise of any warrants. HTBX: 0.80 (+0.17)
These Penny Stocks to Watch Should Be On Your List Friday 3/18/2016, If You Choose
ACCESSWIRE - Fri Mar 18, 11:12AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 18, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. CLF, ECR, TBIO, and HTBX have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, NASDAQ, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
HTBX: 0.80 (+0.17), ECR: 4.32 (+0.17), TBIO: 0.58 (-0.01), CLF: 5.25 (+0.16)
Heat Biologics Announces Public Offering of Common Stock and Warrants
GlobeNewswire - Fri Mar 18, 7:30AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that it has priced an underwritten public offering of 9,100,000 shares of its common stock and warrants to purchase up to an aggregate of 6,825,000 shares of its common stock at a combined public offering price of $0.75 per share and related warrant. Each share of its common stock is being sold together with a warrant to purchase 0.75 of a share of its common stock. The gross proceeds from this offering to Heat are expected to be approximately $6.8 million, before deducting the underwriting discount and estimated offering expenses payable by Heat, but excluding the exercise of any warrants. HTBX: 0.80 (+0.17)
Penny Stocks to Buy on St. Patrick's Day... If You So Choose
ACCESSWIRE - Thu Mar 17, 10:54AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 17, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. HTBX, CLF, BTU, and ELTP have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
HTBX: 0.80 (+0.17), BTU: 2.07 (unch), CLF: 5.25 (+0.16)
Heat Biologics' CSO to Participate in the 27th Annual Cancer Progress Conference by Defined Health
GlobeNewswire - Wed Mar 09, 6:00AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat's Chief Scientific Officer, will participate in the 27 Annual Cancer Progress Conference by Defined Health being held in New York City. Dr. Schreiber will serve as a speaker on a panel entitled "Immuno-Oncology I: Attacking Cancer Antigens - Exploiting off-the-Shelf and Personalized Vaccines and Triggering of Immunogenic Cell Death," which takes place today at 9:15 a.m. Eastern Time. HTBX: 0.80 (+0.17)
Heat Biologics Presents Positive ComPACT Preclinical Data at the Keystone Symposia
GlobeNewswire - Mon Mar 07, 3:05PM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that positive preclinical data from its next generation ComPACT platform technology, which combines a T cell priming vaccine and T cell co-stimulator in a single product, were presented as both an oral presentation and poster at the Keystone Symposia on Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, held in Whistler, British Columbia, Canada on March 6-10, 2016. Data presented showed that ComPACT secreting OX40L generated the most potent immune response among other ComPACT co-stimulator variations including TL1A, 4-1BBL and ICOSL, as well as compared to systemic delivery of OX40 agonist antibody and vaccine alone. HTBX: 0.80 (+0.17)
Heat Biologics to Present at the 28th Annual ROTH Conference
GlobeNewswire - Fri Mar 04, 6:00AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is scheduled to present at the 28 Annual ROTH Conference on Tuesday, March 15, 2016 at 7:30 a.m. Pacific Time. HTBX: 0.80 (+0.17)
FDA Lifts Heat Biologics Partial Clinical Hold
GlobeNewswire - Wed Feb 10, 6:00AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the company's Phase 2 clinical trial evaluating HS-410 either alone or in combination with standard of care Bacillus Calmette-Guerin (BCG), for the treatment of non-muscle invasive bladder cancer (NMIBC). Heat will resume patient enrollment. HTBX: 0.80 (+0.17)
HIV-1 Infection - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8h7d/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Beth Israel Deaconess Medical Center, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Chipscreen Biosciences Ltd - CompleGen, Inc. - Critical Outcome Technologies Inc. - Cytodyn Inc. - Dong-A ST Co., Ltd. - Enzo Biochem, Inc. - Evofem, Inc. - FIT Biotech Oy - Formune S.L. - Frontier Biotechnologies Co., Ltd - GeneCure LLC - Genetic Immunity, Inc - Gilead Sciences, Inc. - GlaxoSmithKline Plc - H-Phar S.A. - Heat Biologics, Inc. - (20 Others) For more information visit http://www.researchandmarkets.com/research/px..._infection
HTBX: 0.80 (+0.17), ARGS: 5.60 (+0.14), ENZ: 5.92 (+0.15), GILD: 83.37 (+0.92), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)
Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference
GlobeNewswire - Tue Jan 26, 6:02AM CST
-- Early results support mechanism of action
HTBX: 0.80 (+0.17)
